ArticleFrontline gastroenterology2022
No-biopsy pathway following the interim BSG guidance reliably diagnoses adult coeliac disease.
Article in Frontline gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06283264 (Assessment of Coeliac Disease in Patients With Type 2 Diabetes), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Coeliac Disease in Patients With Type 2 Diabetes
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Biopsy-Sparing Diagnosis of Coeliac Disease Based on Endomysial Antibody Testing and Clinical Risk Assessment.Alimentary pharmacology & therapeutics · 2025Article
- Patient preferences for the diagnosis of coeliac disease: A discrete choice experiment.United European gastroenterology journal · 2025Article
- Insights into coeliac disease diagnosis: a 2021-2023 overview of diagnostic approach and delays in children in Slovenia.Wiener medizinische Wochenschrift (1946) · 2024Article
- Non-biopsy Strategy for the Diagnosis of Celiac Disease in Adults: A Narrative Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Review
- Navigating coeliac disease diagnosis in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024Article
- Cost-benefits and environmental impact of the no-biopsy approach for the diagnosis of coeliac disease in adults.Frontline gastroenterology · 2024Article
- No-biopsy diagnostic approach to coeliac disease.Gastroenterology and hepatology from bed to bench · 2023Review
- No-biopsy strategy for coeliac disease is applicable in adult patients: a 'real-world' Scottish experience.Frontline gastroenterology · 2023Article
- No-biopsy approach to the diagnosis of coeliac disease.Frontline gastroenterology · 2023Article
- Letter: the BSG COVID-19 interim coeliac disease guidance no-biopsy approach is safe in adults.Alimentary pharmacology & therapeutics · 2021Article
- Do gastroenterologists have medical inertia towards coeliac disease? A UK multicentre secondary care study.BMJ open gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent interim guidance from the British Society of Gastroenterology, aligned to historical paediatric practice, advises a no-biopsy protocol (NBP) for adults with high anti-tissue transglutaminase (tTG-IgA) titres and other clinical factors. A 7-year retrospective review identified 433 patients with positive tTG-IgA. Of these 433, 98 (23%) fulfilled the high titre criteria for an NBP which may have reduced endoscopic burden on the service. A high titre versus low titre translated in a 95% versus 75% histological confirmation of coeliac disease (p<0.01). The addition of anti-endomysial antibody analyses impacted minimally on these predictive rates. Our data support an NBP approach for selected patients. Of concern, however, was the finding that a third of patients with positive titres were not referred for a biopsy despite national guidance at the time advocating it. A clear message needs to be transmitted that the NBP is only for those with high titre, as opposed to any tTG-IgA positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.